Epidemiology  ||| S:0 E:13 ||| NNP
of  ||| S:13 E:16 ||| IN
immune-mediated  ||| S:16 E:32 ||| JJ
inflammatory  ||| S:32 E:45 ||| JJ
diseases ||| S:45 E:53 ||| NNS
:  ||| S:53 E:55 ||| :
incidence ||| S:55 E:64 ||| NN
,  ||| S:64 E:66 ||| ,
prevalence ||| S:66 E:76 ||| NN
,  ||| S:76 E:78 ||| ,
natural  ||| S:78 E:86 ||| JJ
history ||| S:86 E:93 ||| NN
,  ||| S:93 E:95 ||| ,
and  ||| S:95 E:99 ||| CC
comorbidities  ||| S:99 E:113 ||| JJ
Immune-mediated  ||| S:113 E:129 ||| JJ
inflammatory  ||| S:129 E:142 ||| JJ
diseases  ||| S:142 E:151 ||| NNS
( ||| S:151 E:152 ||| -LRB-
IMID ||| S:152 E:156 ||| NNP
)  ||| S:156 E:158 ||| -RRB-
present  ||| S:158 E:166 ||| VB
a  ||| S:166 E:168 ||| DT
group  ||| S:168 E:174 ||| NN
of  ||| S:174 E:177 ||| IN
common  ||| S:177 E:184 ||| JJ
and  ||| S:184 E:188 ||| CC
highly  ||| S:188 E:195 ||| RB
disabling  ||| S:195 E:205 ||| VBG
chronic  ||| S:205 E:213 ||| JJ
conditions  ||| S:213 E:224 ||| NNS
that  ||| S:224 E:229 ||| IN
share  ||| S:229 E:235 ||| NN
inflammatory  ||| S:235 E:248 ||| JJ
pathways ||| S:248 E:256 ||| NN
.  ||| S:256 E:258 ||| .
Several  ||| S:258 E:266 ||| JJ
incidence  ||| S:266 E:276 ||| NN
and  ||| S:276 E:280 ||| CC
prevalence  ||| S:280 E:291 ||| JJ
studies  ||| S:291 E:299 ||| NNS
of  ||| S:299 E:302 ||| IN
IMID  ||| S:302 E:307 ||| NNP
during  ||| S:307 E:314 ||| IN
the  ||| S:314 E:318 ||| DT
past  ||| S:318 E:323 ||| JJ
decades  ||| S:323 E:331 ||| NNS
have  ||| S:331 E:336 ||| VBP
reported  ||| S:336 E:345 ||| VBN
a  ||| S:345 E:347 ||| DT
considerable  ||| S:347 E:360 ||| JJ
variation  ||| S:360 E:370 ||| NN
of  ||| S:370 E:373 ||| IN
the  ||| S:373 E:377 ||| DT
disease  ||| S:377 E:385 ||| NN
occurrence  ||| S:385 E:396 ||| NN
among  ||| S:396 E:402 ||| IN
different  ||| S:402 E:412 ||| JJ
populations ||| S:412 E:423 ||| NNS
.  ||| S:423 E:425 ||| .
Overall ||| S:425 E:432 ||| RB
,  ||| S:432 E:434 ||| ,
the  ||| S:434 E:438 ||| DT
estimated  ||| S:438 E:448 ||| JJ
prevalence  ||| S:448 E:459 ||| NN
of  ||| S:459 E:462 ||| IN
IMID  ||| S:462 E:467 ||| NNP
in  ||| S:467 E:470 ||| IN
Western  ||| S:470 E:478 ||| JJ
society  ||| S:478 E:486 ||| NN
is  ||| S:486 E:489 ||| VBZ
5 ||| S:489 E:490 ||| CD
% ||| S:490 E:491 ||| NN
-7 ||| S:491 E:493 ||| CD
% ||| S:493 E:494 ||| NN
.  ||| S:494 E:496 ||| .
This  ||| S:496 E:501 ||| DT
article  ||| S:501 E:509 ||| NN
provides  ||| S:509 E:518 ||| VBZ
an  ||| S:518 E:521 ||| DT
overview  ||| S:521 E:530 ||| NN
of  ||| S:530 E:533 ||| IN
studies  ||| S:533 E:541 ||| NNS
of  ||| S:541 E:544 ||| IN
the  ||| S:544 E:548 ||| DT
incidence ||| S:548 E:557 ||| NN
,  ||| S:557 E:559 ||| ,
prevalence ||| S:559 E:569 ||| NN
,  ||| S:569 E:571 ||| ,
natural  ||| S:571 E:579 ||| JJ
history ||| S:579 E:586 ||| NN
,  ||| S:586 E:588 ||| ,
and  ||| S:588 E:592 ||| CC
comorbidities  ||| S:592 E:606 ||| NN
of  ||| S:606 E:609 ||| IN
IMID ||| S:609 E:613 ||| NNP
.  ||| S:613 E:615 ||| .
